Resverlogix Announces Filing of Quarterly Financia
Post# of 301275
CALGARY, Alberta, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX ) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management’s Discussion & Analysis for the quarter ended October 31, 2017 with Canadian securities regulatory authorities.
Copies of these documents may be obtained online at www.sedar.com , or the Company's website, www.resverlogix.com , or by emailing ir@resverlogix.com
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX ).
Follow us on Twitter: https://twitter.com/resverlogix_rvx
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.com
(0)
(0)